The purpose of this study is to identify factors that distinguish children with autism from children with developmental delay and those with normal development. This study will also assess the effectiveness of a therapy program designed to help children with autism.

Condition	Treatment or Intervention	Phase
Autism	Behavior: Intensive behavioral therapy	Phase I

Further Study Details: 

Expected Total Enrollment:  48

Children with autism often suffer from social, educational, and functional problems. By understanding the social, linguistic, psychological, and physiological differences that distinguish between autistic children, developmentally delayed children, and children with typical development, researchers may be able to recognize autism early in life so that children with autism can be helped as early as possible and their long-term outcome can be improved.

Children in this study will be enrolled for 2 years. They will receive annual evaluations throughout the two-year period. They will undergo a magnetic resonance imaging (MRI) scan and will complete various activities to determine brain functioning. In addition, children with autism will take part in intensive behavioral therapy at least 4 hours every day for the duration of the study. Communication and social behavior scales, an early development interview, observations of parent/child interaction, and neuropsychological, cognitive, and adaptive behavioral measures will be used to assess participants.

Ages Eligible for Study:  18 Months   -   24 Months,  Genders Eligible for Study:  Both

Accepts Healthy Volunteers

Criteria

Inclusion Criteria for Autistic Participants:

• Diagnosis of autism

Inclusion Criteria for Developmentally Delayed Participants:

• Exhibiting current delays in development

Inclusion Criteria for Participants with Normal Development:

• Exhibiting normal development

Inclusion Criteria for All Participants:

• Overall good health

Washington
      University of Washington, Seattle,  Washington,  98195,  United States; Recruiting

Study chairs or principal investigators

Geraldine Dawson, PhD,  Principal Investigator,  University of Washington   

Study ID Numbers:  1U54MH066399-01A1; U54 MH066399
Record last reviewed:  January 2005
Last Updated:  January 12, 2005
Record first received:  August 26, 2004
ClinicalTrials.gov Identifier:  NCT00090415
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08